Latest Feature

Big data and personalized medicine: Q&A with Definiens CEO Thomas Heydler

Definiens CEO Thomas Heydler discusses his ambition to position his company at the forefront of the coming revolution in personalized and predictive medicines.

The making of an icon | Dr. Tom Fogarty's obsession with innovation

Medtech icon Dr. Tom Fogarty tells about his unconventional path from upstart tinkerer in the suburbs of Cincinnati to healthcare celebrity in the heart of Silicon Valley, in Part 1 of a 3-part series.

DNA analysis in your pocket - Q&A with QuantuMDx founder Jonathan O'Halloran

QuantuMDx envisions a future where laboratory-quality diagnostics are mobile, cheap and available to everyone, from healthcare providers in developing countries to parents dealing with ill children.

Medical device tax: At least $510B paid in 2013

A analysis of reported payments for the medical device tax last year finds that 14 companies accounted for more than 97% of the nearly $500 million collected.

Breathing easier with SinuSys | MassDevice Q&A

SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Listen to Stryker's Q1 2014 earnings call

April 23, 2014 by MassDevice staff

Officials at Stryker discuss the company's Q1 2014 earnings. The company reported profits of $70 million, or 18¢ per share, on sales of $2.31 billion for the 3 months ended March 31, for profit loss of 77% on sales growth of 5.3%.

Recall charges continue to suck up Stryker's profits

April 23, 2014 by Arezu Sarvestani

Orthopedics giant Stryker reports a 77% decline in profits in its 1st quarter, driven largely by continued charges associated with hip implant and waste management system recalls.

Recall charges take a chunk out of Stryker's bottom line in Q1

Michigan orthopedics giant Stryker (NYSE:SYK) lost a little Wall Street love today after posting 1st-quarter earnings that fell shy of analysts' expectations.

Intuitive Surgical sinks following rough Q1 report

April 23, 2014 by Arezu Sarvestani

Wall Street flees from Intuitive Surgical after the company posts disappointing 1st quarter earnings.

Intuitive Surgical sinks following dismal earnings

Intuitive Surgical (NSDQ:ISRG) dropped more than 11% today as Wall Street reacted to the surgical systems maker's disappointing 1st-quarter earnings. +3 | The top 3 medtech stories for Apr. 23, 2014

April 23, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.


Sotera aims for $54M for continuous patient monitoring

April 23, 2014 by Arezu Sarvestani

Patient monitoring systems maker Sotera Wireless is looking for another $33.2 million to close a $53.9 million fundraising round.

Sotera aims for $54M for continuous patient monitoring

California-based Sotera Wireless is looking to raise $53.9 million in an ongoing funding round, with about $20.7 million raised as of Monday, regulatory filings show.

Allergan resists $47B offer by swallowing poison pill

April 23, 2014 by Arezu Sarvestani

Aesthetics company Allergan adopts a "poison pill" shareholder plan in order to fend off an unsolicited $47 billion offer from Valeant Pharmaceuticals and activist investor Pershing Square Capital Management.

Allergan fends off hostile $47B offer by swallowing poison pill

Aesthetics products maker Allergan (NYSE:AGN) last night adopted a "poison pill" strategy designed to insulate the company from a surprise $47 billion hostile takeover.

FDA may ban behavioral shock devices

April 23, 2014 by Arezu Sarvestani

U.S. healthcare regulators will meet tomorrow to consider banning the use of electrical shocking devices used in behavior modification.

FDA to consider banning behavioral electric shocks

The FDA's neurological devices panel will meet tomorrow to decide the fate of aversive electrical stimulation, devices that generate electrical shocks used by care providers in order to deter unwanted behavior.

Will Medicare patients be left out of the bionics revolution?

April 23, 2014 by Brian Johnson

We're in the middle of a revolution in prosthetics, with true bionic integration just over the horizon. But a hidebound Medicare could prevent thousands of amputees from receiving the cutting-edge - and costly - devices.

A version of this story was originally posted on

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp